FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022

FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes dominant service provider in sub-Saharan Africa

DURHAM, NORTH CAROLINA — FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO.

The global company will continue to be known as FHI Clinical, and FHI Clinical SA (Pty) Ltd is the operational arm of FHI Clinical in South Africa. Ted FitzGerald continues to lead FHI Clinical and FHI Clinical SA as Chief Executive Officer. Abraham Van Wyk joins the executive team as Managing Director, FHI Clinical SA, in addition to Sanchia Theron as Global Head, Medical Affairs, and Leonard Herbst, Global Head, Project Management.
Headquartered in Centurion (Gauteng), South Africa, FHI Clinical SA provides significant access to the South Africa market—a competitive market with significant growth opportunity. South Africa accounts for most of the clinical trial activity in sub-Saharan Africa with the majority being infectious disease (ID) therapeutic studies. This acquisition allows FHI Clinical to further expand its share of the ID market and become the dominant service provider in sub-Saharan Africa, showcasing South Africa as a clinical trial destination.

FHI Clinical will maintain its global headquarters in Durham, NC with additional operations in 12 countries. The company now employs approximately 450 staff, with approximately 285 employees based in East and West Africa.

About FHI Clinical

FHI Clinical is a full-service contract research organization (CRO) with the global expertise, responsive approaches and proven solutions to manage complex clinical research around the world. Benefitting from our 50+ year history of clinical research, our team of approximately 450 global staff has worked on studies in more than 70 countries. As problem solvers, forward thinkers and on-the-ground members of those communities, we are dedicated to helping you find solutions to the research challenges that have kept life-saving therapies from at-risk populations. Visit fhiclinical.com or contact us at info@fhiclinical.com or 919.321.3321 to learn how we can put our diverse clinical and operational expertise to work for you.

news archive

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read More »

Share this post

Share on linkedin
Share on twitter
Share on facebook